The groundbreaking success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but betting in companies strongly reliant on generic versions presents a uncertain picture. Although early profits were substantial, the expiration of patents and the appearance of less expensive alternatives have eroded the customer base. Consequently,